[ad_1]
Business Wire India
The fresh surge in COVID-19 cases has now confirmed that the second wave of the coronavirus pandemic is here and is expanding its footprints in India.
The study by the Centre for Cellular and Molecular Biology (CCMB) and CSIR-Institute of Microbial Technology (I M Tech) proved the presence of Coronavirus in air samples in Covid-19 wards of hospitals.
Several other studies done earlier also proved the presence of other pathogenic airborne viruses, bacteria and fungi in ICU and wards.
SARS-CoV2 enters humans using ACE 2 (Angiotensin converting enzyme 2) receptors present in the nose and mouth. Inhibition or regulation of ACE2 receptors potentially be effective in the treatment of COVID-19.
Secretory IgA plays a crucial role in the immune defence of mucosal surfaces, the first point of entry of SARS-CoV-2.
IgA is in fact the most important immunoglobulin to fight infectious pathogen in respiratory system and digestive system at the point of pathogen entry. As an immune barrier, secretory IgA can neutralize SARS-CoV-2 before they reach and bind the epithelial cells.
Naturally available bioflavonoid compounds with high bioavailability and low cytotoxicity are the most efficient candidates to inhibit ACE2 receptors and boost IgA to prevent the entry of CoV-2 in to host cells, neutralize the virus and break the chain of Covid-19 transmission.
Flavonoids were intensively investigated for having bioactivity beneficial to health, such as anti-inflammatory, anticancer, antioxidant, antimicrobial, antiviral and immunomodulating properties.
Many of them showed significant antiviral responses in both in vitro and in vivo studies. Naringenin and hesperetin (flavanon), hesperidin (flavanonone glycoside), neohesperidin (flavone glycoside), nobiletin (O-methylation), are amongst natural ACE2 inhibitors.
Citrobioshield containing citrus bioflavonoids has been clinically tested and proven effective on Covid-19 patients, Coronavirus, bacteria and fungi.
Fogging / fumigation using a suitable antimicrobial will reduce the viral / bacterial / fungal loads in ICU and wards.
Hospitals use antimicrobials such as Formaldehyde, Glutaraldehyde, Hydrogen peroxide, Quaternary ammonium compounds, Chlorine compounds for fogging / fumigation to control infections. But these toxic and corrosive chemicals are not suitable for use in the presence of human beings. Hence, many hospitals where the patient turnover is high, do not do fogging / fumigation regularly. This is the reason for the increase in the Coronaviral load in ICU / ward and other critical areas.
Repeated exposure to increased Coronaviral loads resulted in increased death rate in healthcare personnel, especially the doctors.
'Citrobioshield Natural & Organic Antimicrobial' which contains citrus flavonoids has been found to be very useful to control the infections in ICU, ward, operation theatre etc without shifting the patients. Its safety and efficacy have already been tested in various labs and hospitals. 'Citrobioshield' has also been clinically tested and proven effective on COVID-19 patients and Coronavirus as per ICMR guidelines.
Advantages of 'Citrobioshield' fogging: 1. No need to shift the patients from ICU during the procedure. 2. Effectively decreases the viral loads in the air and on the surface. 3. Inhalation of fog kills the viruses present in the nose, mouth and eyes and helps the patient to recover fast. Thus, it can be used for both prevention and control of Coronavirus and other pathogens.
As 'Citrobioshield' can be very safely used in hospitals and other places to control Coronavirus, we suggest the government and private hospitals to use 'Citrobioshield' fogging / fumigation to control COVID-19.
Citrobioshield is manufactured by GermKill India Labs LLP (https://www.germkillindia.com), Bengaluru.
To know more about Citrobioshield-https://youtu.be/IFcBOpWBKn8
[ad_2]
Source link
Virter is a dynamic Virtual Reporter specializing in technology, startups, and emerging trends in the digital world. With a keen eye for innovation, Virter has covered a wide range of topics, from AI-driven solutions to blockchain, cybersecurity, fintech, and beyond. Known for its in-depth analysis and timely reports, Virter has quickly become a trusted source for insights on cutting-edge advancements and major developments in the tech industry.
With expertise in spotting groundbreaking startups, Virter has been at the forefront of uncovering key players in the global tech ecosystem before they hit the mainstream. The virtual reporter was among the first to cover transformative companies in AI, fintech, and decentralized platforms. Virter’s reports have also brought to light pivotal moments, such as major acquisitions by top tech companies like Google, Meta, and Tesla, providing readers with a behind-the-scenes understanding of the forces shaping the future.
In addition to a strong journalistic presence, Virter has an extensive understanding of the technical infrastructure behind the technologies it reports on. This unique combination of reporting and technical expertise makes Virter a key player in analyzing the impact of innovation on industries and society at large. Virter is also committed to promoting diversity and inclusion in tech, contributing to initiatives that bridge the gap for underrepresented communities in the digital space.
Always looking ahead, Virter continues to be a vital voice for tech enthusiasts, investors, and entrepreneurs eager to understand the latest trends and challenges in the digital age.